Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review

<h2>ABSTRACT</h2> Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease with a complex a multifactorial pathophysiology. Due to difficulty recognising patients with SLE in an early stage, diagnostic delay is very common, which can result in the accumulation of organ damage. Some immunological signs, such as the presence of autoantibodies, have previously been shown to be present in patients with SLE, even before the onset of the first symptoms. This makes these immunological signs a prime target to improve the diagnostic process. In this article, we review recent studies investigating the use of biomarkers for diagnostics, including autoantibodies, other serum biomarkers, biomarkers in other bodily materials, circulating RNAs, and gene expression profiles. We discuss their place in the pathophysiology of SLE and their potential to improve and expedite the diagnostic process for patients with SLE.

Authors

Institutions

Publication Details

Journal
EULAR Rheumatology Open
Published
2026-02-09
DOI
https://doi.org/10.1016/j.ero.2025.11.025
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review

Tammo Brunekreef, Henny G. Otten, Maarten Limper, Jacob M. van Laar
EULAR Rheumatology Open
Systemic Lupus Erythematosus Research
article

Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review

Tammo Brunekreef, Henny G. Otten, Maarten Limper, Jacob M. van Laar
article en

Abstract

<h2>ABSTRACT</h2> Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease with a complex a multifactorial pathophysiology. Due to difficulty recognising patients with SLE in an early stage, diagnostic delay is very common, which can result in the accumulation of organ damage. Some immunological signs, such as the presence of autoantibodies, have previously been shown to be present in patients with SLE, even before the onset of the first symptoms. This makes these immunological signs a prime target to improve the diagnostic process. In this article, we review recent studies investigating the use of biomarkers for diagnostics, including autoantibodies, other serum biomarkers, biomarkers in other bodily materials, circulating RNAs, and gene expression profiles. We discuss their place in the pathophysiology of SLE and their potential to improve and expedite the diagnostic process for patients with SLE.

EULAR Rheumatology OpenVol. 2(1)
University Medical Center Utrecht (NL)
Good health and well-being
Openalex Percentile: Top 64%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review — Tammo Brunekreef, Henny G. Otten, et al. · EULAR Rheumatology Open (2026) | TGRS Research Map | TGRS